Select a Region North America

A European Commercial Readiness Opportunity Assessment​

27 Markets, 1 Unified Launch Strategy

Launching in Europe can be complex. With 27 countries and profound differences between them, how can you ensure an optimal launch?

Traditional approaches to launch sequencing need re-evaluation due to multiple changes occurring across the region. Countries are increasingly interconnected, with decisions taken in one market having a ripple effect across multiple markets.

Reduce Risk with a Comprehensive European Launch Strategy

Price, reimbursement, and access are critical to commercial readiness in European markets.

Without a strategy to address all three, pharma and biotech companies have limited success in what is a critical market. That’s why EVERSANA has created a fixed-fee“European Commercial Readiness Opportunity Assessment” to help companies develop optimal launch plans, powered by deep market expertise and propriety data & software powered by our industry-leading NAVLIN by EVERSANA platform.

Powered by data and software, we can help you deliver stakeholder value with:

EVERSANA’s team of EU launch experts can help you optimize your launch with early planning, market understanding, entry strategy, and launch sequence optimization.

Contact us today to learn more about how we can support your commercialization in Europe.

CASE STUDY: Optimizing Launch & Maximizing Revenue Potential in Europe

Check out how our team of European experts helped a client develop a solid strategy to support the launch of their rare oncology indication asset.

Related Articles

Successfully Navigating Self-Commercialisation in Europe
Successfully Navigating Self-Commercialisation in Europe

Introduction As discussed in our previous paper, Successful Launches in Europe: Complex, But Not Complicated?,,  Europe is one of the world’s largest and most important regions of focus for pharmaceutical and biotechnology manufacturers looking to treat patients and maximise the value of their products. However, the challenges of entering this market, particularly in terms of […]

Read now: Successful Launches in Europe: Complex, But Not Complicated?
Successful Launches in Europe: Complex, but Not Complicated?

Europe represents a major pharmaceutical market – it accounts for 22% of the global market, second only to the U.S. in terms of market size and has a large population of over 500 million. Understandably, pharmaceutical and biotechnology companies looking to maximise their revenue consider Europe to be a key focus[1]. Indeed, looking at first-time […]

A Holistic Launch in Europe Is Possible, But Change Is Necessary

Unless you live in Europe or have commercialized a product in this region, you may not realize that the European pharmaceutical market is a huge contributor to global health, and it is currently undergoing market-wide changes. Here are a few key facts to know about Europe’s pharmaceutical markets: Europe’s population is more than double that […]